Analysis · Health
A strong weight-loss result can coexist with a large safety evidence gap
By AWEI · AI-compiled · Published · Analysis prepared · 1 source · doi.org
CagriSema had the largest estimated weight reduction in a 2024 diabetes review, yet its estimate for stopping treatment because of side effects was too uncertain to establish whether discontinuation increased or decreased. The same treatment could have convincing evidence for one outcome and leave another largely unresolved.
Haiqiang Yao and colleagues’ BMJ systematic review combined 76 randomised trials involving 39,246 adults with type 2 diabetes. It examined 15 GLP-1 drugs and related treatments. Trials lasted 12 to 78 weeks, and different outcomes drew on different subsets of the evidence.
For CagriSema, which combines semaglutide with cagrilintide, the estimated weight reduction beyond placebo was 14.03 kg, with a 95% confidence interval of 11.00 to 17.05 kg. The authors rated confidence in that estimate as high. But the odds ratio for discontinuation due to adverse events was 0.84, with an interval stretching from 0.03 to 26.63. That range accommodates both substantially lower and substantially higher odds; it cannot establish a tolerability advantage.
Nor did uncertain discontinuation evidence mean an absence of symptoms. The review found higher odds of nausea, vomiting and diarrhoea with CagriSema than with placebo, although those estimates also had wide intervals. Experiencing a side effect and stopping treatment because of it are distinct outcomes.
The researchers used network meta-analysis, connecting direct trial comparisons with indirect comparisons through shared treatments. Randomisation supports treatment-effect estimates, but indirect comparisons require sufficiently comparable studies. Some treatments had few studies; populations and follow-up varied, and some trials had blinding shortcomings or other potential biases.
The practical lesson is to check uncertainty separately for each outcome. A precise benefit estimate cannot fill a safety evidence gap. These findings concern adults with type 2 diabetes over the studied periods; they do not establish an individual’s expected weight change or long-term tolerability.
Sources used for this article (1)
Direct links to the publisher reports used to prepare this article.
- Source 1
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis Haiqiang Yao, Anqi Zhang, Delong Li …
